NCT01992536已完成2 期
Phase 2, Observer-Blind, Placebo-Controlled, Randomized, Multi-Center Extension Study to Evaluate the Safety and Immunogenicity of a Booster Dose of a MenABCWY Vaccine Administered 24 Months Following the Primary Series to Adolescents and Young Adults Who Participated in V102_03 (NCT01272180)
Novartis Vaccines26 个研究点 分布在 2 个国家目标入组 194 人开始时间: 2013年12月最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 194
- 试验地点
- 26
- 主要终点
- 2. Percentage of Subjects With HT-hSBA Titers ≥ 1:5 Against Strains of N. Meningitidis Serogroups B.
研究概览
简要总结
The purpose of this extension study is to evaluate the immunogenicity and safety of a booster dose of a MenABCWY vaccine, administered 24 months after completion of the primary vaccination series, in subjects who previously received the same vaccine formulation in study V102_03 (NCT01272180) (Groups I and II). Antibody persistence at 24 and 36 months after the primary vaccination and 12 months after the booster dose will also be evaluated in these subjects.
In addition, safety and immunogenicity of two investigational MenABCWY vaccine formulations (either a MenABCWY+ OMV or a MenABCWY+¼ OMV) will be assessed in subjects who previously received two doses of MenB vaccine (Group III) or one dose of Menveo vaccine (Group IV). These subjects will be followed for safety and immunogenicity for 12 months after vaccination in study V102_03E1.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Prevention
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 10 Years 至 25 Years（Child, Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Males and females that received both vaccinations and completed the Study Termination visit in the primary study, V102_03 (NCT01272180);
- •Individuals or the individual's parents or legal guardian who have given written consent after the nature of the study has been explained according to local regulatory requirements;
- •Individuals who have given written assent as required by local regulations after the nature of the study has been explained to them according to local regulatory requirements;
- •Individuals in good health as determined by the outcome of medical history, physical examination and clinical judgment of the investigator;
- •Individuals and/or or the individual's parents or legal guardian who can comply with study procedures and are available for follow-up.
排除标准
- •History of any meningococcal vaccine administration other than the vaccination administered in the primary study, V102_03 (NCT01272180);
- •Current or previous, confirmed or suspected disease caused by N. meningitidis;
- •Household contact with and/or intimate exposure to an individual with any laboratory confirmed N. meningitidis infection within 60 days of enrollment;
- •History of severe allergic reactions after previous vaccinations or hypersensitivity to any vaccine component;
- •All sexually active females that have not used an "acceptable contraceptive method(s)" for at least 2 months prior to study entry. Acceptable birth control methods are defined as one or more of the following:
- •Hormonal contraceptive (such as oral, injection, transdermal patch, implant, cervical ring)
- •Barrier (condom with spermicide or diaphragm with spermicide) each and every time during intercourse
- •Intrauterine device (IUD)
- •Monogamous relationship with vasectomized partner. Partner must have been vasectomized for at least six months prior to the subject's study entry;
- •Sexually active females that refuse to use to an "acceptable contraceptive method" through to 3 weeks following the study vaccination;
- •Female subjects with a positive pregnancy test prior to the study vaccine being administered;
- •Nursing (breastfeeding) mothers;
- •Individuals with a history of illness or with an ongoing illness that, in the opinion of the investigator, may pose additional risk to the subject if he/she participates in the study;
- •Any serious, chronic, or progressive disease (e.g., neoplasm, diabetes, cardiac disease, hepatic disease, progressive neurological disease or seizure disorder; autoimmune disease, HIV infection or AIDS, blood dyscrasias, bleeding diathesis, signs of cardiac or renal failure, or severe malnutrition);
- •Subjects who required chronic administration (defined as more than 14 days) of immunosuppressants or other immune-modifying drugs within six months prior to the study vaccination. (For corticosteroids, this means prednisone, or equivalent, ≥ 20mg/day. Inhaled and topical steroids are allowed).
- •Receipt of blood, blood products and/or plasma derivatives, or a parenteral immunoglobulin preparation within the previous 90 days;
- •Individuals participating in any clinical trial with another investigational product 30 days prior to first study visit or intent to participate in another clinical study at any time during the conduct of this study;
- •Administration or planned administration, of any vaccine not foreseen by the study protocol within 30 days prior study vaccination, and up to 30 days after the vaccination (with the exception of any licensed influenza vaccine which may be administered >14 days preceding or >14 days following the study vaccination);
- •Individuals who study personnel or immediate family members of study personnel including brother, sister, child, parent, or the spouse.
- •Individuals who have experienced moderate or severe acute infection and/or fever (defined as temperature ≥ 38°C) within 3 days prior to enrolment.
- •Who have received systemic antibiotic treatment within 7 days prior to enrollment.
结局指标
主要结局
2. Percentage of Subjects With HT-hSBA Titers ≥ 1:5 Against Strains of N. Meningitidis Serogroups B.
时间窗: Day 1 and Day 30
Percentage of subjects reporting HT-hSBA titers ≥ 1:5 against strains of N. meningitidis serogroups B at baseline (Day 1) and one month (Day 30) following administration of a booster dose of MenABCWY, in the present study, in subjects who previously received the same MenABCWY vaccine formulation in study V102_03 (NCT01272180).
1. Percentages of Subjects With HT-hSBA (High-throughput Human Serum Bactericidal Assay) Seroresponse Against N. Meningitidis Serogroups A, C, W and Y.
时间窗: Day 30
Percentages of subjects having HT-hSBA seroresponse against N. meningitidis serogroups A, C, W and Y, following administration of a booster dose of MenABCWY, in the present study, in subjects who previously received the same MenABCWY vaccine formulation in study V102_03 (NCT01272180). Seroresponse to N. meningitidis serogroups A, C, W and Y is defined as: for subjects with a pre-vaccination HT-hSBA titer \< 1:4, a post-vaccination hSBA titer ≥ 1:8; for subjects with a pre-vaccination hSBA titer ≥ 1:4, an increase in hSBA titer of at least four times the pre-vaccination titer.
次要结局
- 14. Percentage of Subjects With HT-hSBA Titer ≥ 1:5 to N. Meningitidis Strains of Serogroup B(Day 1, Day 30 and Day 365)
- 4. Percentage of Subjects With HT-hSBA Titer ≥ 1:5 to N. Meningitidis Strains of Serogroup B.(Day 1 (Pre vaccination))
- 3. Percentage of Subjects With HT-hSBA Titer ≥ 1:8 to N. Meningitides Serogroups A, C, W, Y.(Day 1 (Pre vaccination))
- 5. The HT-hSBA Geometric Mean Titers (GMTs) Against N. Meningitidis Serogroups A, C, W,Y.(Day 1 (Pre-vaccination))
- 21. The HT-hSBA GMTs Against Neisseria Meningitidis Strains of Serogroups B.(Day 1, Day 30 and Day 365)
- 23. Number of Subjects With Solicited Local and Systemic Adverse Events Following Booster Vaccination in This Study.(From day 1 (6 hours) through day 7 after any vaccination)
- 11. Percentage of Subjects With HT-hSBA Titer ≥ 1:5 Against N. Meningitidis Serogroup B Strains.(Day 1 and Day 30)
- 12. Percentage of Subjects With Seroresponse to N. Meningitidis Serogroups A, C, W and Y, at Day 30 After Booster Vaccination in This Study.(Day 30)
- 13. Percentage of Subjects With HT-hSBA Titer ≥ 1:8 to N. Meningitidis Serogroups A, C, W,Y.(Day 1 and Day 365)
- 22. Percentage of Subjects With HT-hSBA Titer ≥ 1:8 to N. Meningitidis Serogroups A,C,W,Y at 12 Months After Booster Vaccination.(Day 1, Day 30 and Day 365)
- 7. The HT-hSBA GMTs Against N. Meningitidis Serogroups A, C, W, Y.(Day 1 and Day 30)
- 8. The HT-hSBA GMTs Against N. Meningitidis Strains of Serogroups B.(Day 1 and Day 30)
- 9. Percentage of Subjects With Four-fold Rise in HT-hSBA Titers Against N. Meningitidis Serogroup B Strains.(Day 1 and Day 30)
- 17. The HT-hSBA GMTs Against N. Meningitidis Strains of Serogroups B.(Day 1 and Day 365)
- 20. The HT-hSBA GMTs Against Neisseria Meningitidis Serogroups A, C, W,Y and Strains of Serogroups B.(Day 1, Day 30 and Day 365)
- 6. The HT-hSBA GMTs Against N. Meningitidis Strains of Serogroup B.(Day 1 (Pre-vaccination))
- 10. Percentage of Subjects With HT-hSBA Titer ≥ 1:8 Against N. Meningitidis Serogroups A,C,W,Y.(Day 1 and Day 30)
- 15. Percentage of Subjects With Four-fold Rise in HT-hSBA Titers Against N. Meningitidis Serogroup B Strains.(Day 1, Day 30 and Day 365)
- 16. The HT-hSBA GMTs Against N. Meningitidis Serogroups A, C, W, Y.(Day 1 and Day 365)
- 18. Percentage of Subjects With HT-hSBA Titer ≥ 1:8 to N. Meningitidis Serogroups A, C, W,Y.(Day 1, Day 30 and Day 365)
- 19. Percentage of Subjects With HT-hSBA Titer ≥ 1:5 to N. Meningitidis Strains of Serogroup B.(Day 1, Day 30 and Day 365)
- 24. Number of Subjects With Unsolicited (Any AEs and Possibly Related AEs) Following Booster Vaccination in This Study.(Day 1 through Day 30)
- 26. Number of Subjects With Unsolicited Adverse Leading to New Onset Chronic Disease (NOCD) Before Study Vaccination.(From primary parent study completion up to Day 1 in this study.)
- 25. Number of Subjects With Unsolicited Adverse Events Following Booster Vaccination in This Study.(Day 1 to Day 365)
研究者
研究点 (26)
Loading locations...
相似试验
已完成
2 期
A Study to Evaluate the Safety and Immunogenicity of Booster With AZD1222, mRNA-1273, or MVC-COV1901 Against COVID-19COVID-19 VaccineNCT05197153Medigen Vaccine Biologics Corp.804
已完成
1 期
A Study to Evaluate the Safety, Tolerability, and Immunogenicity of MVC-COV1901 or MVC-COV1901(Beta) Against COVID-19COVID-19 VaccineNCT05216601Medigen Vaccine Biologics Corp.107
已完成
2 期
A Study on the Safety and Immune Response of Investigational COVID-19 mRNA Vaccines in Healthy AdultsNCT05960097GlaxoSmithKline692
已完成
2 期
Safety, Tolerability and Immunogenicity of a Third Dose of One of Four Different Formulations of rMenB + MenACWY Combination Vaccine in Adolescents Who Previously Received the Same Study VaccinesMeningococcal DiseaseMeningococcal MeningitisNCT01367158Novartis Vaccines440
已完成
2 期
Immunogenicity and Safety of a Booster Vaccination With a Recombinant Protein RBD Candidate Vaccine Against SARS-CoV-2 in Healthy Adults Volunteers Fully Vaccinated Followed by an Extension Period to Study a Fourth Dose Administration.COVID-19SARS-CoV-2 Acute Respiratory DiseaseNCT05142553Hipra Scientific, S.L.U887